Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Neurogene Analyst Ratings and Price Targets | NASDAQ:NGNE | Benzinga
Neurogene Inc has a consensus price target of $59.8 based on the ratings of 6 analysts. The high is $72 issued by Leerink Partners on November 12, 2024. The low is $45 issued by BMO Capital on November 20, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and BMO Capital on March 25, 2025, November 25, 2024, and November 20, 2024, respectively. With an average price target of $50 between HC Wainwright & Co., HC Wainwright & Co., and BMO Capital, there's an implied 259.97% upside for Neurogene Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BMO Capital
Stifel
Leerink Partners
Baird
1calculated from analyst ratings
Analyst Ratings for Neurogene
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | 259.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $50 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 295.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | 223.97% | BMO Capital | Keith Tapper20% | $60 → $45 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 295.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | 331.97% | Stifel | Paul Matteis43% | $44 → $60 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 331.97% | BMO Capital | Keith Tapper20% | $65 → $60 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 418.36% | Leerink Partners | Mani Foroohar45% | $45 → $72 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 418.36% | Baird | Joel Beatty69% | $54 → $72 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 295.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $49 → $55 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 252.77% | HC Wainwright & Co. | Mitchell Kapoor44% | $51 → $49 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 367.96% | BMO Capital | Keith Tapper20% | → $65 | Initiates | → Outperform | Get Alert |
| 06/20/2024 | Buy Now | 267.17% | HC Wainwright & Co. | Mitchell Kapoor44% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/11/2024 | Buy Now | 288.77% | Baird | Joel Beatty69% | → $54 | Initiates | → Outperform | Get Alert |
| 06/04/2024 | Buy Now | 267.17% | HC Wainwright & Co. | Mitchell Kapoor44% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 267.17% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $51 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 295.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 295.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 04/29/2024 | Buy Now | 231.17% | Leerink Partners | Mani Foroohar45% | → $46 | Initiates | → Outperform | Get Alert |
| 03/21/2024 | Buy Now | — | William Blair | Sami Corwin11% | — | Initiates | → Outperform | Get Alert |
| 03/19/2024 | Buy Now | 295.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $45 → $55 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 223.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 01/17/2024 | Buy Now | 223.97% | HC Wainwright & Co. | Mitchell Kapoor44% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2024 | Buy Now | 223.97% | HC Wainwright & Co. | Mitchell Kapoor44% | → $45 | Initiates | → Buy | Get Alert |
| 01/05/2024 | Buy Now | 123.18% | Stifel | Paul Matteis43% | → $31 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Neurogene (NGNE) stock?
The latest price target for Neurogene (NASDAQ:NGNE) was reported by HC Wainwright & Co. on March 25, 2025. The analyst firm set a price target for $50.00 expecting NGNE to rise to within 12 months (a possible 259.97% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neurogene (NGNE)?
The latest analyst rating for Neurogene (NASDAQ:NGNE) was provided by HC Wainwright & Co., and Neurogene maintained their buy rating.
When was the last upgrade for Neurogene (NGNE)?
There is no last upgrade for Neurogene
When was the last downgrade for Neurogene (NGNE)?
There is no last downgrade for Neurogene.
When is the next analyst rating going to be posted or updated for Neurogene (NGNE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurogene was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Neurogene (NGNE) correct?
While ratings are subjective and will change, the latest Neurogene (NGNE) rating was a maintained with a price target of $55.00 to $50.00. The current price Neurogene (NGNE) is trading at is $13.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.